Large gap with delayed quotes
|
Last quote
08/30/2025
-
02:00:00
|
Bid
08/29/2025 -
21:59:59
|
Bid Volume |
Ask
08/29/2025 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
161.71
+1.75
(
+1.09% )
|
161.71
|
400 |
161.81
|
1,500 |
Analysis date: 29.08.2025
Global Evaluation
Slightly positive
Slightly positive
The stock is classified in the slightly positive zone since 10.06.2025.
Interest
Strong
Strong
Three stars since 08.08.2025.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 08.08.2025 at a price of 150.06.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 10.06.2025.
4wk Rel Perf
21.50%
21.50%
The four-week dividend-adjusted overperformance versus SP500 is 21.50%.
Sensibility
Low
Low
The stock has been on the low-sensitivity level since 28.02.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.10%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.45%.
Mkt Cap in $bn
3.17
3.17
With a market capitalization between $2 & $8bn, LIGAND PHARMA is considered a mid-cap stock.
G/PE Ratio
0.79
0.79
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.9 indicates that investors must pay a premium for the estimated growth potential:
LT P/E
19.77
19.77
The estimated PE is for the year 2026.
LT Growth
15.69%
15.69%
The annualized growth estimate is for the current year to 2026.
Avg. Nb analysts
5
5
Over the last seven weeks, an average of 5 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
102
102
For 1% of index variation, the stock varies on average by 1.02%.
Correlation
0.53
0.53
52.85% of stock movements are explained by index variations.
Value at Risk
19.41
19.41
The value at risk is estimated at USD 19.41. The risk is therefore 12.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
29.08.2014
29.08.2014